Twist Bioscience (NASDAQ:TWST) Stock: Insider Dennis Cho Sells 348 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 348 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $165.49, for a total transaction of $57,590.52. Following the transaction, the insider directly owned 73,303 shares of the company’s stock, valued at $12,130,913.47. The trade was a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The shares were sold at an average price of $122.62, for a total value of $50,519.44.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $184.03 on Friday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $185.22. The company has a market cap of $11.54 billion, a PE ratio of -82.90 and a beta of 2.22. The stock has a 50 day simple moving average of $125.11 and a 200-day simple moving average of $86.46. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the prior year, the business earned $0.33 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Twist Bioscience News Roundup

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist’s partnership with Eli Lilly’s TuneLab AI-driven drug-discovery platform, under which Twist will serve as a preferred antibody-characterization data provider, strengthens its exposure to pharmaceutical research and artificial-intelligence applications. Twist Bioscience Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
• Positive Sentiment: The company’s latest quarterly results showed revenue of $118.4 million, up 23.2% year over year, while full-year revenue guidance was raised. Those results provide fundamental support for the recent rally, although Twist remains unprofitable and missed the latest quarterly EPS estimate.
• Neutral Sentiment: TWST recently reached a new 12-month high, making the shares vulnerable to consolidation as investors lock in gains after the partnership-driven advance. Twist Bioscience Hits New 12-Month High
• Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, implying no measurable short-covering pressure. Because the figure conflicts with the article’s description of a “significant increase,” investors should treat the data cautiously.
• Negative Sentiment: CEO Emily Leproust sold 1,687 shares, while SVP Paula Green and insider Dennis Cho sold 294 and 348 shares, respectively, at about $165.49. The filings state the sales were intended to cover tax withholding on vested equity awards, and each executive retained a substantial position, reducing—but not eliminating—the negative signal. SEC insider transaction filings
• Negative Sentiment: Quiver data shows 87 insider sales and no purchases over the past six months. Combined with ongoing losses and a stock price well above many analyst targets, the pattern may weigh on momentum and valuation-sensitive investors.

Institutional Trading of Twist Bioscience

A number of large investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. bought a new position in shares of Twist Bioscience in the second quarter valued at $277,000. Engineers Gate Manager LP bought a new stake in shares of Twist Bioscience during the 2nd quarter worth $3,333,000. Integrated Wealth Concepts LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter worth $99,000. Allworth Financial LP raised its position in shares of Twist Bioscience by 54.9% during the second quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after purchasing an additional 213 shares during the period. Finally, Nykredit A S acquired a new stake in shares of Twist Bioscience during the second quarter worth $283,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on TWST shares. Robert W. Baird increased their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Evercore lowered shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a research note on Monday, July 6th. Guggenheim reiterated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 24th. Canaccord Genuity Group raised their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Finally, UBS Group initiated coverage on Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $103.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.